VTVT
vTv Therapeutics Inc.
Biotechnology
Market Cap$261M
5Y Perf.-73.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VTVT vs PRTA
Revenue, margins, valuation, and 5-year total return — side by side.
PRTA
Prothena Corporation plc
Biotechnology
Market Cap$567M
5Y Perf.-1.2%
VTVT vs PRTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VTVT | PRTA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $261M | $567M |
| Revenue (TTM) | $-24K | $58M |
| Net Income (TTM) | $-27M | $-151M |
| Gross Margin | — | -39.7% |
| Operating Margin | — | -210.6% |
| Forward P/E | — | 42.7x |
| Total Debt | $0.00 | $14M |
| Cash & Equiv. | $89M | $308M |
VTVT vs PRTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VTVT
PRTA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| vTv Therapeutics In… (VTVT) | 100 | 26.9 | -73.1% |
| Prothena Corporatio… (PRTA) | 100 | 98.8 | -1.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VTVT vs PRTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VTVT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Prothena Corporation plc is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
VTVT
vTv Therapeutics Inc.
The Income Pick
VTVT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.81
- Lower volatility, beta 0.81, current ratio 13.54x
- Beta 0.81, current ratio 13.54x
Best for: income & stability and sleep-well-at-night
PRTA
Prothena Corporation plc
The Growth Play
PRTA is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -92.8%, EPS growth -99.6%, 3Y rev CAGR -43.6%
- -73.0% 10Y total return vs VTVT's -87.0%
- -92.8% revenue growth vs VTVT's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRTA | -92.8% revenue growth vs VTVT's -100.0% |
| Quality / Margins | VTVT | 2.1% margin vs PRTA's -260.9% |
| Stability / Safety | VTVT | Beta 0.81 vs PRTA's 0.96 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | VTVT | +52.5% vs PRTA's +44.4% |
| Efficiency (ROA) | PRTA | -42.3% ROA vs VTVT's -43.5% |
VTVT vs PRTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
VTVT vs PRTA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRTALAGGINGVTVT
VTVTvTv Therapeutics Inc.
0leads
PRTAProthena Corporation …
2leads
6 Total Categories
CATEGORYLEADERvs VTVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRTA2/2
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRTA4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRTA leads this category, winning 2 of 2 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRTA and VTVT operate at a comparable scale, with $58M and -$24,000 in trailing revenue. On growth, PRTA holds the edge at +17.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VTVTvTv Therapeutics … | PRTAProthena Corporat… |
|---|---|---|
| RevenueTrailing 12 months | -$24,000 | $58M |
| EBITDAEarnings before interest/tax | -$33M | -$121M |
| Net IncomeAfter-tax profit | -$27M | -$151M |
| Free Cash FlowCash after capex | -$25M | -$85M |
| Gross MarginGross profit ÷ Revenue | — | -39.7% |
| Operating MarginEBIT ÷ Revenue | — | -2.1% |
| Net MarginNet income ÷ Revenue | — | -2.6% |
| FCF MarginFCF ÷ Revenue | — | -147.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.4% | +17.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.9% | +153.6% |
PRTA leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
Evenly matched — VTVT and PRTA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | VTVTvTv Therapeutics … | PRTAProthena Corporat… |
|---|---|---|
| Market CapShares × price | $261M | $567M |
| Enterprise ValueMkt cap + debt − cash | $173M | $273M |
| Trailing P/EPrice ÷ TTM EPS | -9.70x | -2.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 42.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 58.54x |
| Price / BookPrice ÷ Book value/share | 4.06x | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — VTVT and PRTA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRTA leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
PRTA delivers a -49.9% return on equity — every $100 of shareholder capital generates $-50 in annual profit, vs $-74 for VTVT. On the Piotroski fundamental quality scale (0–9), VTVT scores 3/9 vs PRTA's 1/9, reflecting mixed financial health.
| Metric | VTVTvTv Therapeutics … | PRTAProthena Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -73.8% | -49.9% |
| ROA (TTM)Return on assets | -43.5% | -42.3% |
| ROICReturn on invested capital | — | -21.0% |
| ROCEReturn on capital employed | -56.4% | -47.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | -$89M | -$294M |
| Cash & Equiv.Liquid assets | $89M | $308M |
| Total DebtShort + long-term debt | $0 | $14M |
| Interest CoverageEBIT ÷ Interest expense | -5408.17x | — |
PRTA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — VTVT and PRTA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRTA five years ago would be worth $4,277 today (with dividends reinvested), compared to $3,142 for VTVT. Over the past 12 months, VTVT leads with a +52.5% total return vs PRTA's +44.4%. The 3-year compound annual growth rate (CAGR) favors VTVT at -0.2% vs PRTA's -48.5% — a key indicator of consistent wealth creation.
| Metric | VTVTvTv Therapeutics … | PRTAProthena Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | -21.6% | +14.5% |
| 1-Year ReturnPast 12 months | +52.5% | +44.4% |
| 3-Year ReturnCumulative with dividends | -0.5% | -86.3% |
| 5-Year ReturnCumulative with dividends | -68.6% | -57.2% |
| 10-Year ReturnCumulative with dividends | -87.0% | -73.0% |
| CAGR (3Y)Annualised 3-year return | -0.2% | -48.5% |
Evenly matched — VTVT and PRTA each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VTVT and PRTA each lead in 1 of 2 comparable metrics.
Risk & Volatility
VTVT is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than PRTA's 0.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRTA currently trades 90.1% from its 52-week high vs VTVT's 70.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VTVTvTv Therapeutics … | PRTAProthena Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 0.96x |
| 52-Week HighHighest price in past year | $44.00 | $11.69 |
| 52-Week LowLowest price in past year | $14.00 | $4.32 |
| % of 52W HighCurrent price vs 52-week peak | +70.5% | +90.1% |
| RSI (14)Momentum oscillator 0–100 | 41.1 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 61K | 474K |
Evenly matched — VTVT and PRTA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates VTVT as "Buy" and PRTA as "Buy". Consensus price targets imply 80.4% upside for PRTA (target: $19) vs 65.4% for VTVT (target: $51).
| Metric | VTVTvTv Therapeutics … | PRTAProthena Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $51.33 | $19.00 |
| # AnalystsCovering analysts | 14 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRTA leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
Best OverallProthena Corporation plc (PRTA)Leads 2 of 6 categories
Loading custom metrics...
VTVT vs PRTA: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is VTVT or PRTA a better buy right now?
For growth investors, Prothena Corporation plc (PRTA) is the stronger pick with -92.
8% revenue growth year-over-year, versus -100. 0% for vTv Therapeutics Inc. (VTVT). Analysts rate vTv Therapeutics Inc. (VTVT) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VTVT or PRTA?
Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -57.
2%, compared to -68. 6% for vTv Therapeutics Inc. (VTVT). Over 10 years, the gap is even starker: PRTA returned -73. 0% versus VTVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VTVT or PRTA?
By beta (market sensitivity over 5 years), vTv Therapeutics Inc.
(VTVT) is the lower-risk stock at 0. 81β versus Prothena Corporation plc's 0. 96β — meaning PRTA is approximately 19% more volatile than VTVT relative to the S&P 500.
04Which is growing faster — VTVT or PRTA?
By revenue growth (latest reported year), Prothena Corporation plc (PRTA) is pulling ahead at -92.
8% versus -100. 0% for vTv Therapeutics Inc. (VTVT). On earnings-per-share growth, the picture is similar: vTv Therapeutics Inc. grew EPS 0. 0% year-over-year, compared to -99. 6% for Prothena Corporation plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VTVT or PRTA?
vTv Therapeutics Inc.
(VTVT) is the more profitable company, earning 0. 0% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VTVT leads at 0. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PRTA leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is VTVT or PRTA more undervalued right now?
Analyst consensus price targets imply the most upside for PRTA: 80.
4% to $19. 00.
07Which pays a better dividend — VTVT or PRTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is VTVT or PRTA better for a retirement portfolio?
For long-horizon retirement investors, vTv Therapeutics Inc.
(VTVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Both have compounded well over 10 years (VTVT: -87. 0%, PRTA: -73. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between VTVT and PRTA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(VTVT: -241.2% · PRTA: 1706.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.